3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Lymphoid
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Breast Neoplasms
5
Lung Neoplasms
4
Colorectal Neoplasms
4
Prostatic Neoplasms
3
Multiple Myeloma
2
Lymphoma
2
Gastrointestinal Neoplasms
2
Support of the Family as a Caregiving System
1
Stomach Neoplasms
1
Sarcoma
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Otorhinolaryngologic Neoplasms
1
Neuroendocrine Tumors
1
Neoplasms
1
Mixed Dementias
1
Meningeal Carcinomatosis
1
Malignant Female Reproductive System Neoplasm
1
Lymphoma, Follicular
1
Localized Head and Neck Carcinoma
1
Lewy Body Disease
1
Kidney Neoplasms
1
Head and Neck Neoplasms
1
Esophageal Neoplasms
1
Disease
1
Dementia, Vascular
1
Dementia
1
Cognitive Dysfunction
1
Cigarette Smoking-Related Carcinoma
1
Cardiovascular Diseases
1
Interventions
pembrolizumab
14
Nivolumab
10
Ipilimumab
10
Axitinib
6
cabozantinib
5
belzutifan
5
Radiosurgery
5
atezolizumab
4
Sunitinib
4
palbociclib
3
lenvatinib
3
Surveys and Questionnaires
3
Radiotherapy
3
Pluvicto
3
Everolimus
3
Blood Specimen Collection
3
Biopsy
3
zimberelimab
2
pazopanib
2
cemiplimab
2
Therapeutics
2
Methods
2
Magnetic Resonance Spectroscopy
2
Irinotecan
2
2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid
2
trebananib
1
toripalimab
1
tocilizumab
1
temsirolimus
1
spartalizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Kidney Neoplasms
×
Referral and Consultation
×
1 year
×
Clear all
NCT02821793
2025-07-01
PRIORITY
Institut Bergonié
Completed
346 enrolled
9 charts